September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration and the Risk of Stroke: A 5-Year Follow-up Cohort Study
Author Affiliations & Notes
  • Sung Soo Kim
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Tyler Hyungtaek Rim
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Christopher Seungkyu Lee
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • SungChul Lee
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Do Wook Kim
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Hyun Ju Park
    Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Sung Soo Kim, None; Tyler Rim, None; Christopher Lee, None; SungChul Lee, None; Do Wook Kim, None; Hyun Ju Park, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 547. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sung Soo Kim, Tyler Hyungtaek Rim, Christopher Seungkyu Lee, SungChul Lee, Do Wook Kim, Hyun Ju Park; Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration and the Risk of Stroke: A 5-Year Follow-up Cohort Study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):547.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the risk of stroke following ranibizumab treatment for neovascular age-related macular degeneration (AMD).

Methods : National registry data were used, comprising 1,025,340 random subjects in 2002. The ranibizumab group was composed of patients diagnosed with neovascular AMD and treated with ranibizumab between 2009 and 2013 (n=467). The two types of comparison groups were defined as comorbidity-matched controls (n=2,330) comprised of randomly selected patients (five per AMD patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n=2,248) comprised according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used

Results : Strokes occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio [HR] =0.88; 95% confidence interval [CI], 0.60–1.30; HR=0.95, 95% CI, 0.65–1.41, respectively).

Conclusions : Ranibizumab treatment for neovascular AMD did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×